100 mg Blister
Pregabalin Capsule
Product Images NDC 60687-506
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60687-506). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
100 mg Carton
This is a medication package containing 100 capsules (10 x 10) of Pregabalin, with each capsule containing 100mg of the active ingredient. The medication is only available through prescription and is intended for oral ingestion. The usual dosage instructions are enclosed in the package insert. The medication should be stored at a temperature range of 20°C to 25°C or between 59°F to 86°F, with the requirement to protect it from excessive heat or cold. The package contains a blister pack with medication capsules, and it is advised not to use it if the blister pack is broken. The package also contains a medication guide that the pharmacist should provide to each patient alongside the drug product. The package is manufactured by American Health Packaging of Columbus, Ohio.*
150 mg Blister
Description:
This appears to be a list of medication names, strengths, and perhaps manufacturers that may have been obtained via Optical Character Recognition () scanner or software. The text is not clear and contains errors that make it difficult to provide a comprehensive description.*
150 mg Carton
This is a description of a medication named "Pregabalin" in the form of capsules. The package contains 100 capsules arranged in 10 strips of 10 capsules each, and the recommended dose is 150mg per capsule. The medication comes with a medication guide to be given to each patient. The package has specific storage instructions; it should be stored between 20 to 25 degrees Celsius (or 83 to 77 degrees Fahrenheit) with excursions permitted between 15 to 50 degrees Celsius (or 59 to 85 degrees Fahrenheit). The medication should be kept out of reach of children. The package includes a warning to not use the medication if the blister is in a broken form. The details of the medication's manufacturer, NBC+ 64080-414, are provided on the package. The medication is packaged and distributed by American Health Packaging in Columbus, Ohio.*
25 mg Blister
25 mg Carton
This is a description of a medication with the NDC code 60687-473-01 that contains Pregabalin. It comes in a package of 100 capsules that are only available with a prescription. Each capsule contains 25mg of Pregabalin, and the usual dosage information can be found in the package insert. It is recommended to store the medication between 20°C and 25°C, and excursions are permitted between 15°C and 30°C. The medication should be kept out of reach of children and should not be used if the package is torn or damaged. The medication is packaged and distributed by American Health Packaging in Columbus, Ohio.*
50 mg Blister
50 mg Carton
This is a prescription drug with the NDC code 60687-484-01. It is Pregabalin in capsule form with 100 capsules per pack (10x10). Each capsule contains 75mg of the drug. The usual dosage is mentioned as 50 packages in the prescribing information. The drug should be stored between 0 and 30°C (32-86°F) with controlled room temperature. The package also includes a warning to keep the drug out of children's reach. The manufacturer is American Health Packaging based in Columbus, Ohio.*
75 mg Blister
This is a list of capsules of different strengths of the medication Pregabalin.*
75 mg Carton
NDC 60687-495-01 is a prescription drug containing Pregabalin in capsule form. Each package contains 100 capsules, consisting of 10 strips of 10 capsules each. The recommended dosage instructions are mentioned in the package insert. The drug must be stored between 20°C to 25°C, and excursions are permitted between 15°C to 30°C. The package must be kept out of reach of children. The drug product is manufactured by Rising Pharmaceuticals Inc. and packaged and distributed by American Health Packaging, Columbus, Ohio. The drug package contains a medication guide that the pharmacist needs to dispense to each patient along with the medication.*
Ahp47301
Ahp48401
Ahp49501
Ahp50602
Ahp51702
Cockcroft And Gault Equation
Figure 1
Figure 10
This appears to be a graph showing the estimated percentage of subjects without LTR (likely to relapse) over time, comparing Pregabalin to Placebo. The percentage of subjects without LTR begins at 0 on the first day and steadily increases over time, with Pregabalin showing a higher percentage than Placebo. The graph covers a time period of around 180 days.*
Figure 11
Figure 12
Figure 2
The text shows a table of results from a clinical trial comparing the effectiveness of pregabalin 100 mg three times daily versus placebo, in improving pain in patients. The results are displayed in percentages, with the percent of patients improved being 100, and the percent of improvement in pain from baseline ranging from 0 to 100.*
Figure 3
This is a chart showing the percentage of patients who improved after taking Pregabalin at different doses (300mg,150mg and 75mg, three times a day) and a Placebo. It also indicates the percentage of improvement in pain from the baseline.*
Figure 4
This is a chart indicating the percentage of patients who experienced improvement in pain from the baseline after taking Pregabalin at a dose of 200 mg or 100 mg three times a day compared to a placebo. The chart shows percentages ranging from 0% to 100% on the vertical axis and different numeric values on the horizontal axis.*
Figure 5
This is a graph showing the percentage of patients who experienced improvement in pain from their baseline levels after taking Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo. The x-axis shows the range of percentage improvement (from 0 to 100), while the y-axis shows the number of patients. The graph displays various data points for each treatment option.*
Figure 6
This text provides responder rates (%) for studies E1 and E3. The responder rate for study E1 is 60%. The responder rate for study E3 ranged from 0% to 51%, and statistical significance was observed compared to the placebo. However, some of the text is not readable due to errors.*
Figure 7
Figure 9
The text presents a chart showing the percentage of patients who improved while taking different doses of Pregabalin or placebo. The chart also provides information on the percentage improvement in pain from baseline.*
Structure
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
